VXRT

COVID-19 Oral Vaccine

COVID-19

Stage (next event)

Expected Date

Phase 1 Data

Q4 2020/Q1 2021

Catalyst Info & Data Links

TITLE: COVID-19 Oral Vaccine - Phase 1 Data

  • ClinicalTrial.gov (NCT04563702): Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults


WHAT IS THE NEXT CATALYST EVENT?


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • Q4 2020/Q1 2021 (Est.)


PRIOR DATA
PRESS RELEASES

Mechanism of Action

MECHANISM OF ACTION / RATIONALE

  • Our vaccine platform is a replication-defective adenovirus type-5 vectored vaccine that expresses antigen along with a novel toll-like receptor 3 agonist as an adjuvant. These vaccines have been well tolerated, and able to generate robust humoral and cellular immune responses to the expressed antigens

Updated by HC

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon